BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32955830)

  • 1. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
    Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
    Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
    Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
    J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
    Aminov S; Giricz O; Melnekoff DT; Sica RA; Polishchuk V; Papazoglu C; Yates B; Wang HW; Sahu S; Wang Y; Gordon-Mitchell S; Leshchenko VV; Schinke C; Pradhan K; Aluri S; Sohn M; Barta SK; Agarwal B; Goldfinger M; Mantzaris I; Shastri A; Matsui W; Steidl U; Brody JD; Shah NN; Parekh S; Verma A
    J Clin Invest; 2024 Feb; 134(8):. PubMed ID: 38376944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults.
    Kegyes D; Ghiaur G; Bancos A; Tomuleasa C; Gale RP
    Crit Rev Oncol Hematol; 2024 Apr; 196():104317. PubMed ID: 38437908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.
    Abou Dalle I; Jabbour E; Short NJ
    Ther Adv Hematol; 2020; 11():2040620720910023. PubMed ID: 32215194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No free rides: management of toxicities of novel immunotherapies in ALL, including financial.
    Jain T; Litzow MR
    Blood Adv; 2018 Nov; 2(22):3393-3403. PubMed ID: 30482769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
    Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
    N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.
    Balsat M; Cacheux V; Carre M; Tavernier-Tardy E; Thomas X
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):879-891. PubMed ID: 33016157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine in acute lymphoblastic leukemia.
    Pui CH
    Front Med; 2020 Dec; 14(6):689-700. PubMed ID: 33074527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease.
    Curran E; O'Brien M
    Semin Hematol; 2020 Jul; 57(3):157-163. PubMed ID: 33256906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to the treatment of older adults with acute lymphoblastic leukemia.
    Schwartz M; Wieduwilt MJ
    Semin Hematol; 2020 Jul; 57(3):122-129. PubMed ID: 33256901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020.
    Rank CU; Schmiegelow K
    Semin Hematol; 2020 Jul; 57(3):102-114. PubMed ID: 33256899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
    Oehler VG
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):228-236. PubMed ID: 33275713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review.
    Szakács Z; Hegyi PJ; Farkas N; Hegyi P; Balaskó M; Erős A; Szujó S; Pammer J; Mosdósi B; Simon M; Nagy A; Für G; Hussain A
    PLoS One; 2020; 15(12):e0243045. PubMed ID: 33270732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
    Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
    Jiang H; Hu Y; Mei H
    Biomark Res; 2020 Nov; 8(1):66. PubMed ID: 33292685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic analysis reveals a lncRNA-miRNA-mRNA network associated with dasatinib resistance in chronic myeloid leukemia.
    Luo J; Gao Y; Lin X; Guan X
    Ann Palliat Med; 2021 Feb; 10(2):1727-1738. PubMed ID: 33302634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
    Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent updates for antibody therapy for acute lymphoblastic leukemia.
    Li L; Wang Y
    Exp Hematol Oncol; 2020 Nov; 9(1):33. PubMed ID: 33292550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.